A 2-year open-label second extension study to evaluate the safety, tolerability and efficacy of canakinumab (ACZ885) an anti-interleukin-1β monoclonal antibody in patients with active rheumatoid arthritis

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2008
This article has no abstract
Epistemonikos ID: 4e98bc7cdf51c5de93bf7a4b8d30e6f81bdb6e07
First added on: Jan 22, 2025